Targanta Therapeutics targanta.com


Public lists: Pharma Startups (4743)

Targanta Therapeutics, Inc. (NASDAQ:TARG) is a biotechnology company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Targanta's lead drug candidate, Oritavancin, has completed two Phase III clinical trials in complicated skin and skin structure infections and is under study for additional indications and unique treatment regimens.

Targanta Therapeutics, Inc. (NASDAQ:TARG) is a biotechnology company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Targanta's lead drug candidate, Oritavancin, has completed two Phase III clin...Show all

Company (Acquired)

Phone: 617-577-9020

Fax:

222 Third Street
Suite 2300
Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Targanta Therapeutics $20.1M Feb 26, 2009
See all 22 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Targanta Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 11 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 22 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections Aug 11, 2006 Mar 26, 2013 Patent